|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | siRNA targeting Livin decreases tumor in a xenograft model for colon cancer显示文摘AIM: To evaluate the effect of silencing Livin gene expression with siRNA to apoptosis and proliferation in a colon cancer cell line.METHODS: To investigate the anticancer effect of silencing Livin gene expression, we established an siRNA transfected cell line using the HCT116 colon cancer cell line. After confirming the successful transfection, MTT assay, flow cytometry and annexin V staining were employed to evaluate the antiapoptotic effect. To confirm the in vivo effect of Livin-siRNA, different doses of LivinsiRNA were injected into xenografted tumors in BALB/c nude mice model.RESULTS: Livin expression was dramatically decreased after siRNA transfection, especially at 25 μmol/L of siRNA, but this suppression was not dose-dependent. The cell count at 18 h after transfection was significantly reduced as compared with controls (P < 0.01), but tended not to decrease proportionally depending on transfected doseor time. MTT assay revealed that silencing the Livin gene suppressed cellular proliferation at 18 h after transfection (P = 0.04); however, the inhibitory effect disappeared thereafter. Also, there was no significant difference in cel- lular proliferation depending on siRNA dose. The rate of apoptosis also increased with silencing of the Livin gene. In vivo , the tumor size significantly decreased after Livin- siRNA injection at 20 μmol/L concentration (P = 0.03). There were no significant body weight changes of mice after siRNA injection. Histologic examination revealed no significant toxic reaction in kidney, liver and brain of mice. CONCLUSION: siRNA-mediated downregulation of Livin expression can induce apoptosis in colon cancer in vitro and in vivo , which suggests the possibility of new cancer therapeutics using siRNA. | Bo-Young Oh Ryung-Ah Lee Kwang Ho Kim | 2011 | World Journal of Gastroenterology2011，17，20： | 15 |
| 2 | ^(18)F-DG PET/CT in detection of recurrence and metastasis ofcolorectal cancer显示文摘AIM: To evaluate the value of 18F-DG PET/CT in detecting recurrence and/or metastasis of colorectal cancer (CRC). METHODS: Combined visual analysis with semiquantitative analysis, the 18F-DG PET/CT whole- body imaging results and the corresponding clinical data of 68 postoperative CRC patients including 48 male and 20 female with average age of 58.1 were analyzed retrospectively. RESULTS: Recurrence and/or metastasis were confirmed in 56 patients in the clinical follow-up after the PET/CT imaging. The sensitivity of PET/CT diagnosis of CRC recurrence and/or metastasis was 94.6%, and the specificity was 83.3%. The positive predictive value (PPV) was 96.4% and the negative predictive value (NPV) was 76.9%. PET/CT imaging detected one or more occult malignant lesions in 8 cases where abdominal/pelvic CT and/or ultrasonography showed negative findings, and also detected more lesions than CT or ultrasonography did in 30.4% (17/56) cases. Recurrence and/or metastasis was detected in 91.7% (22/24) cases with elevated serum CEA levels by 18F-DG PET/CT imaging. CONCLUSION: 18F-DG PET/CT could detect the recurrence and/or metastasis of CRC with high sensitivity and specificity. | Long-Bang Chen Jin-Long Tong Hai-Zhu Song Hong Zhu Yu-Cai Wang | 2007 | World Journal of Gastroenterology2007，13，37： | 11 |
| 3 | Molecular markers and targets for colorectal cancer prevention显示文摘Colorectal 癌症是在世界上的第三很流行的癌症。如果在一个早阶段检测了,治疗可能经常导致痊愈。因为预防比痊愈好,流行病学的研究表明有一本健康食谱经常保护免受支持 / 开发癌症的伤害。在评估新药和设备的重要考虑正在决定一个产品是否能有效地治疗指向的疾病。有相当很多个简历标记,走路进临床的试用,很少正在等候现出症状之前的潜的功效和安全结果进入临床的试用。研究人员们在修改试用设计并且定义正确控制人口正在面对挑战,验证从象为决策的一个指南的生物、分析的观点和使用的简历标记数据的简历标记试金。尽管有遵循所有指南,结果从许多大临床的试用是令人失望的。为了避免这些失望,简历标记的选择和它的目标药,需要为它的毒性和功效在适当动物模型被评估。这评论的焦点在颜色在潜在的分子的目标和他们的简历标记的很少上表面的癌症。biomarkers/surrogate 端点的力量和限制也被讨论。各种各样的小径在肿瘤房间和特定的代理人包含了在简历指向改变的分子的简历标记分子的小径被阐明。为颜色的新兴的新平台 siRNAs 和 miRNAs 技术的重要性表面的癌症治疗学被考察。 | Naveena B JANAKIRAM Chinthalapally V RAO | 2008 | Acta Pharmacologica Sinica2008，29，1： | 5 |
| 4 | MicroRNAs与癌症显示文摘MicroRNAs (miRNAs) belong to a class of noncoding, regulatory RNAs that are involved in oncogenesis and show remarkable tissue specificity.miRNAs are approximately 22 nt non-coding RNAs, which regulate gene expression in a sequence-specific manner via translational inhibition or messenger RNA (mRNA) degradation, thus affecting various cellular processes.Since the discovery of their fundamental mechanisms of action, the field of miRNAs has opened a new era in the understanding of small noncoding RNAs.Recent evidence has shown that miRNA controls cell growth, apoptosis, and differentiation.Cancer is a complex genetic disease caused by abnormalities in gene structure and expression, moreover, miRNA expression correlates with cancers and could have a crucial function in tumor progression.Bioinformatic data indicate that each miRNA can control hundreds of target genes, but identification of the accurate miRNA targets will be crucial to exploit the emerging knowledge of miRNA contribution to cancer process. | Libo Xiao Zhiping Wu Rui Feng Qishun Zhu Chenwei Gao Yan Chen Chun Hou Yonggui Wu | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，9： | 1 |
| 5 | RNA干扰在大肠癌多药耐药中的研究进展显示文摘大肠癌是人类常见的消化系恶性肿瘤,化疗是治疗该病的主要手段之一,但大肠癌细胞对化疗药物的多药耐药性阻碍了该病的治疗进程.RNA干扰能特异性阻断耐药靶基因表达,近年来已逐渐应用于大肠癌多药耐药的基因治疗,并取得了一些突破性的进展.本文就近年RNA干扰在大肠癌多药耐药研究中的应用概况予以综述,以冀对临床治疗有所提示. | 余文燕 许建华 王国娟 张瑞娟 孙珏 范忠泽 | 2012 | 世界华人消化杂志2012，20，30： | 0 |
| 6 | 结直肠癌的基因治疗显示文摘结直肠癌是常见的消化道恶性肿瘤。目前治疗以外科手术为主,辅以放、化疗,术后5年生存率在50%左右。肿瘤基因治疗发展迅速,作为一种新的辅助治疗手段有重要意义。结直肠癌中研究比较多的是免疫基因治疗、自杀基因治疗、抑癌基因的应用等。基因疗法可以有效地杀伤肿瘤细胞,联合传统治疗方法可延长结直肠癌患者的生存时间,提高生活质量。 | 郭贞 徐为 | 2009 | 医学综述2009，15，2： | 0 |
| 7 | 短发夹状RNA对人肝癌细胞环氧合酶-2的抑制作用显示文摘目的:构建针对人环氧合酶-2(COX-2)基因编码区的短发夹状RNA(shRNA)真核表达载体质粒,观察其在不同时间点对人不同肝癌细胞株COX-2表达的影响.方法:以人COX-2mRNA编码区作为RNA干扰靶点,构建shRNA真核表达载体质粒WBH1和WBH2,应用阳离子脂质体分别转染人肝癌细胞株HepG2和Bel7402,利用逆转录聚合酶链反应和Westernblot法分别观察两株细胞转染后24,48,72,和96hCOX-2mRNA和蛋白的表达变化,检测抑制效果.结果:质粒在HepG2细胞和Bel7402细胞中的转染率分别约为60%和54%.WBH1导入细胞24,48,72和96h后,逆转录聚合酶链反应检测COX-2mRNA表达抑制率,HepG2细胞分别为18.5%,88.6%,52.8%和42.4%(P<0.01).Bel7402细胞分别为9%,45.1%,70.1%和56.3%(P<0.01).Westernblot法检测蛋白表达抑制率,HepG2细胞分别为10.3%,80.5%,45.3%和39.0%(P<0.01);Bel7402细胞分别为8.3%,40.2%,66.4%和35.6%(P<0.01).质粒WBH2对COX-2的表达无影响(P>0.05).结论:针对人COX-2的shRNA能高效特异的抑制不同肝癌细胞株的COX-2表达.HepG2细胞和Bel7402细胞分别以48h和72h抑制效果最明显.56.3%(P<0.01).Westernblot法检测蛋白表达抑制率,HepG2细胞分别为10.3%,80.5%,45.3%和39.0%(P<0.01);Bel7402细胞分别为8.3%,40.2%,66.4%和35.6%(P<0.01).质粒WBH2对COX-2的表达无影响(P>0.05).结论:针对人COX-2的shRNA能高效特异的抑制不同肝癌细胞株的COX-2表达.HepG2细胞和Bel7402细胞分别以48h和72h抑制效果最明显. | 王华枫 徐可树 钱伟 汪步海 | 2006 | 世界华人消化杂志2006，14，33： | 0 |
| 8 | siRNA沉默细胞周期蛋白A2基因对骨肉瘤细胞增殖的抑制作用显示文摘目的研究 siRNA 对骨肉瘤 MG-63细胞株及正常成纤维细胞细胞周期蛋白 cyclin A2基因表达的抑制及对细胞增殖的影响。方法设计并化学合成靶向 cyclinA2基因的 siRNA,用oligofectamine 将其转染到骨肉瘤细胞系 MG-63及正常人成纤维细胞(HSF)中,用无义 siRNA 转染作为阴性对照,以单加缓冲液磷酸盐缓冲液(PBS)作为空白对照,实时-聚合酶链反应(PCR)、Western印迹方法检测 cyclinA2基因沉默效果,采用 MTT、RT-PCR、流式细胞、平板克隆培养等方法评价cyclinA2基因表达后被抑制后细胞的生长状态,同时检测细胞 PCNA 及 cyclinB1基因表达的改变。结果 1、10、50、100 nmol/L 浓度的 cyclinA2-siRNA 分别使 MG-63细胞 cyclinA2基因表达降低了9.4%,56.4%,79.2%和84.3%,同时 cyclinA2蛋白表达也相应降低。转染10 nmol/L及50 nmol/LsiRNA 后48 h,MG-63细胞增殖抑制分别达到39.1%及54.9%,细胞周期阻滞于 G0/G1期,平板克隆形成率降低,细胞中增殖细胞核抗原(PCNA)及 cyclinB1的 mRNA 表达水平明显下降。对正常成纤维细胞 HSF,50 nmol/L cyclinA2-siRNA 可抑制58.1%的 cyclinA2基因及蛋白表达,其导致细胞周期出现轻度改变,但细胞的增殖及平板克隆形成能力未受影响。结论 cyclinA2是肿瘤细胞增殖所依赖的关键基因,针对 cyclinA2基因的 siRNA 能有效降低细胞中 cyclinA2 mRNA 及蛋白的表达,其能抑制骨肉瘤细胞的生长而对正常细胞的增殖影响很小,靶向 cyclinA2的 siRNA 有望成为治疗骨肉瘤的新途径。 | 刘叶 范顺武 丁佳逸 赵兴 沈炜亮 | 2007 | 中华医学杂志2007，87，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员